SurModics Earnings: Here’s Why Investors are Ambivalent Now
SurModics Inc. (NASDAQ:SRDX) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company.
SurModics Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 29.41% to $0.22 in the quarter versus EPS of $0.17 in the year-earlier quarter.
Revenue: Rose 2.36% to $14.29 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: SurModics Inc. reported adjusted EPS income of $0.22 per share. By that measure, the company beat the mean analyst estimate of $0.21. It missed the average revenue estimate of $15.03 million.
Quoting Management: Commenting on the results, SurModics’ President and Chief Executive Officer, Gary Maharaj, said, “The third quarter was marked by strong earnings. On the revenue side, given the current sluggish medical device industry dynamics, the business performed in-line with our expectations. Although coronary revenues were lower than anticipated, we are encouraged that diversification into other market segments is gaining traction.”
Key Stats (on next page)…
Revenue decreased 0% from $0 in the previous quarter. EPS decreased 4.35% from $0.23 in the previous quarter.
Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.22 to a profit $0.21. For the current year, the average estimate is a profit of $0.94, which is the same with that ninety days ago.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.